Editor LSA

Comprehensive Trend Analysis on Biotechnology: Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), MannKind Corporation, Incyte Corporation, Ariad Pharmaceuticals, Inc.

 
Repost This

Lewes, DE -- (SBWIRE) -- 07/22/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), MannKind Corporation (NASDAQ:MNKD), Incyte Corporation (NASDAQ:INCY), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA).

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) decreased -1.66% and closed at $126.41 on a traded volume of 3.91 million shares, in comparison to 2.19 million shares of average trading volume. So far this year, the stock is down over 91.41%.

The company has a total market capitalization of $9.19 billion and its total outstanding shares are 72.74 million.

Will ONXX Get Buyers Even After The Recent Rally? Find Out Here

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition.

MannKind Corporation (NASDAQ:MNKD) soared 1.68% and closed at $7.25on a traded volume of 3.62 million shares, whereas its average trading volume is 8.24 million shares. In the last three months, the stock is up 80.08%. The Intra-day range for the stock is $7.05 and $7.30.

Will MNKD Continue To Move Higher? Find Out Here

MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Incyte Corporation (NASDAQ:INCY) jumped up 1.76% and closed at $23.11. So far in three months, the stock is up 6.5%. The 52-week range for the stock is $15.43 and $26.15 and during the previous trading session the stock touched its highest price at $23.11. Its introductory price for the day was $22.55, with the overall traded volume of 1.70 million shares.

Will INCY Continue To Move Higher? Find Out Here

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), after opening its shares at the price of $19.85, jumped up 0.10% to close at $20.02 for the day. The stock moved on a traded volume of 1.59 million shares, in comparison to 2.34 million shares of average trading volume.

The 52-week range for the stock is $15.35 and $25.40 and during the previous trading session the stock touched its highest price at $20.35. Its introductory price for the day was $19.85.

Will ARIA Continue To Move Higher? Find Out Here

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/